USA - NASDAQ:ONVO - US68620A2033 - Common Stock
The current stock price of ONVO is 2.04 USD. In the past month the price decreased by -28.17%. In the past year, price decreased by -83%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.39 | 407.14B | ||
| AMGN | AMGEN INC | 15.54 | 182.93B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.82 | 110.48B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.2 | 72.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 881.16 | 58.91B | ||
| INSM | INSMED INC | N/A | 40.75B | ||
| NTRA | NATERA INC | N/A | 28.78B | ||
| BIIB | BIOGEN INC | 9.63 | 23.63B | ||
| INCY | INCYTE CORP | 16.92 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 20.83B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.08 | 14.54B |
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
ORGANOVO HOLDINGS INC
Suite 100, 11555 Sorrento Valley Road
San Diego CALIFORNIA 92075 US
CEO: Keith Murphy
Employees: 20
Phone: 18582241000
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
The current stock price of ONVO is 2.04 USD. The price increased by 1.49% in the last trading session.
ONVO does not pay a dividend.
ONVO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
ORGANOVO HOLDINGS INC (ONVO) has a market capitalization of 3.47M USD. This makes ONVO a Nano Cap stock.
ChartMill assigns a fundamental rating of 2 / 10 to ONVO. The financial health of ONVO is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ONVO reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 60.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -322.19% | ||
| ROE | -3402.47% | ||
| Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 96.31% and a revenue growth 126.67% for ONVO